LAWRENCE, Mass. and PHILADELPHIA, Nov. 10, 2011 /PRNewswire/ — Booth # 407 at The American Society of Nephrology (ASN)’s Kidney Week 2011 — NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, today announced that Ashita Tolwani, M.D., and William Fissell, M.D., recipients of a NxStage Research Grant, conducted a multi-center study evaluating the removal of Piperacillin during continuous renal replacement therapy (CRRT) in an acute setting for acute kidney injury (AKI) patients. Dr. Tolwani and her colleagues will present interim results of the study, which was partly funded by the grant from NxStage, and the National Institutes of Health in three posters on Thursday, November 10 at The American Society of Nephrology (ASN) Kidney Week 2011.
Because of the significant impact of infection and sepsis on survival of patients undergoing CRRT in the intensive care unit, understanding how CRRT therapy influences the levels of active antibiotics gives clinicians additional insight on how they might manage clinical outcomes for these patients.
NxStage is committed to continuously improving the lives of dialysis patients through innovation and advancement in renal care, often made possible by clinical research such as that conducted by Drs. Tolwani and Fissell, said Jeffrey H. Burbank, chief executive officer of NxStage Medical, Inc. We applaud them on the completion of this important study and look forward to supporting future research in nephrology to help provide better therapies to patients.
Dr. Tolwani is Professor of Medicine at the University of Alabama at Birmingham. Dr. Fissell is an Associate Staff of Nephrology and Hypertension at the Cleveland Clinic.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com/.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 20011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
SOURCE NxStage Medical, Inc.